All Stories

  1. COVID-19 mortality in Africa and Asia
  2. Opinion: Medical education in many low- and middle-income countries needs urgent attention and serious improvement
  3. Advances in HIV Treatment: Long-Acting Antiretrovirals and the Path Toward a Cure
  4. The Digital Health Competencies in Medical Education Framework
  5. Short-Cycle Therapy with Bictegravir/Emtricitabine/Tenofovir Alafenamide in a Small Cohort of Virally Suppressed People Living with HIV: A Long-Term Follow-Up
  6. Trends in publication and collaboration of health-themed systematic reviews before and during the COVID-19 pandemic: A bibliometric study
  7. Acceptability of Switching to Long-Acting Cabotegravir and Rilpivirine Among People Living with HIV on Dolutegravir/Rilpivirine Combination: A Single-Center Experience
  8. Overt and occult hepatitis B virus infection detected among chronic kidney disease patients on haemodialysis at a Tertiary Hospital in Ghana
  9. Short Cycle, Intermittent Therapy: A Valuable Option in Selected, Virologically Suppressed People Living with HIV
  10. Acute liver failure in low-income and middle-income countries
  11. HIV-1 RNA levels in semen of people on ‘short-cycle’ antiretroviral therapy
  12. Successful treatment of persistent SARS-CoV-2 infection with nirmatrelvir/ritonavir plus sotrovimab in four immunocompromised patients
  13. Serum 25‐hydroxyvitamin D and hyaluronic acid levels as markers of fibrosis in patients with chronic liver disease at the main tertiary referral hospital in Ghana: A case‐control study design
  14. Medicine should be learned in a conducive environment
  15. Global research profile on monkeypox-related literature (1962–2022): A bibliometric analysis
  16. Monkeypox: Immune response, vaccination and preventive efforts
  17. Letter to the Editor: Dolutegravir Monotherapy and Body Weight Gain in Antiretroviral Naïve Patients
  18. Acceptance and willingness to purchase a hypothetical COVID-19 vaccine in a region under Shariah law: A cross-sectional study in Aceh, Indonesia
  19. Acute severe hepatitis of unknown etiology in children: A mini-review
  20. Global multi-stakeholder endorsement of the MAFLD definition
  21. Is monoclonal antibody administration necessary in all vaccinated patients with breakthrough COVID‐19 infections?
  22. Research priorities to reduce the impact of COVID-19 in low- and middle-income countries
  23. Chronic liver diseases must be reduced worldwide: it is time to act
  24. Seroprevalence and risk factors for hepatitis B and hepatitis C in three large regions of Kazakhstan
  25. Short-cycle therapy in HIV-infected adults: rilpivirine combination 4 days on/3 days off therapy
  26. Prevalence of liver fibrosis using transient elastography in the general population in Cambodia: a pilot study
  27. Mini-review: Silico-tuberculosis
  28. Short-cycle therapy (5 days on/2 days off) with a lamivudine + dolutegravir regimen in a cohort of virologically suppressed patients with HIV infection
  29. Increase in visceral adipose tissue in a woman living with HIV after introduction of integrase strand transfer inhibitor
  30. Violence Against Healthcare Workers: A Worldwide Phenomenon With Serious Consequences
  31. Acute liver failure
  32. Commentary: Systemic Lupus Erythematosus in Native sub-Saharan Africans: A Systematic Review and Meta-Analysis
  33. HIV and SARS-Coronavirus-2 Epidemics: Possible Interactions and Need for Studies, Especially in Africa
  34. Seroprevalences of autoantibodies and anti-infectious antibodies among Ghana’s healthy population
  35. Alcohol? Not for Non-alcoholic Fatty Liver Disease Patients
  36. Dolutegravir monotherapy and body weight gain in antiretroviral naïve patients
  37. DRIVE-AHEAD Trial’s Results and the Need for a More Appropriate Comparator Drug
  38. Efavirenz dose reduction is associated with improved lipid profile in HIV-1 infected patients
  39. Orphan drugs
  40. Khat-related liver disease in sub-Saharan Africa: neglected, yet important – Authors' reply
  41. Patient-centered Care and Treatment in HIV Infection
  42. Dolutegravir monotherapy: an option for highly adherent HIV1-infected naive patients with relatively low zenith HIV-RNA?
  43. Defensive medicine: It is time to finally slow down an epidemic
  44. Liver cirrhosis in sub-Saharan Africa: neglected, yet important
  45. “High” antiretroviral deintensification, a strategy to avoid drug interactions and unfavourable long-term effects of HAART
  46. Detection of Hepatitis E Antibodies in Kazakhstan: A Pilot Study
  47. The Expanding Therapeutic Perspective of CCR5 Blockade
  48. Dolutegravir monotherapy in HIV-1-suppressed patients: A feasible regimen in real life
  49. Febrile rhabdomyolysis of unknown origin in refugees coming from West Africa through the Mediterranean to Calabria, Italy
  50. Dual therapy with a combination of unboosted atazanavir and lamivudine as maintenance treatment in virologically suppressed HIV ‐1‐infected patients
  51. Dolutegravir monotherapy in HIV-infected naive patients with an HIV-RNA load <100 000 copies/mL: a medium-term follow-up
  52. Cerebral palsy: a multidisciplinary, integrated approach is essential
  53. Dolutegravir 50 mg thrice weekly plus atazanavir 400 mg daily in a long-term virologically suppressed HIV-infected patient
  54. End-stage liver disease in eastern Europe and central Asia: action is needed
  55. Treatment of Acute Liver Failure in Resource-Constrained Settings without Transplantation Facilities Can Be Improved
  56. Dolutegravir Monotherapy in HIV-Infected Naive Patients With <100,000 Copies/mL HIV RNA Load
  57. Tuberculosis-immune reconstitution inflammatory syndrome
  58. Liver diseases in sub-Saharan Africa: the importance of dedicated public clinics
  59. Understanding the HIV/AIDS Atripla drug components interaction with human plasma.
  60. Liver disease in patients with HIV in sub-Saharan Africa
  61. Raltegravir/nevirapine dual therapy at reduced doses as ‘maintenance’ treatment in virally suppressed HIV-infected patients
  62. Mother-to-child transmission of hepatitis B virus in sub-Saharan Africa: time to act
  63. Neurological complications of HIV infection in pre-HAART and HAART era: a retrospective study
  64. Virological Efficacy of a Reduced Dose of Nevirapine in a Small Cohort of Suppressed HIV-1–Infected Patients
  65. Efficacy of a reduced dose of DARUNAVIR/RTV in a cohort of antiretroviral-naïve and experienced HIV-infected patients: a medium-term follow-up
  66. Efavirenz dose reduction in HIV-infected patients
  67. Efficacy of a reduced dose of darunavir/ritonavir in a cohort of antiretroviral-naive and -experienced HIV-infected patients: a medium-term follow-up
  68. Pegylated interferon α plus ribavirin for the treatment of chronic hepatitis C: A multicentre independent study supported by the Italian Drug Agency
  69. Management of chronic hepatitis B in children: An unresolved issue
  70. Comparative chromatography–mass spectrometry studies on the antiretroviral drug nevirapine—Analytical performance characteristics in human plasma determination
  71. Thrombotic Thrombocytopenic Purpura-Haemolytic Uremic Syndrome and pregnancy
  72. A Maintenance Dose of Atazanavir/Ritonavir 200/100 mg Once Daily Is Effective in Virologically Suppressed HIV-1–Infected Patients
  73. Efficacy of a Reduced Dose of Darunavir/Ritonavir in a Small Cohort of Antiretroviral-Naïve HIV-Infected Patients
  74. Cancer control in Africa: which priorities?
  75. Limited Adherence to Antiretroviral Regimens in an Italian Cohort
  76. Can HIV-1 viral interference be used therapeutically?
  77. Dose reduction of antiretrovirals: a feasible and testable approach to expand HIV treatment in developing countries
  78. Isoniazid preventive therapy in human immunodeficiency virus infection [Correspondence]
  79. Efavirenz dose reduction in HIV-infected patients
  80. Antiretroviral Therapy-Associated Diseases Are Common in the Long-Term
  81. A reduced dose of darunavir/ritonavir is effective in PI-experienced HIV-infected patients
  82. Efficacy of Lopinavir-Ritonavir Reduced Dose in HIV-Infected Patients
  83. Tuberculosis and cancer: a complex and dangerous liaison
  84. Stroke: a realistic approach to a growing problem in sub-Saharan Africa is urgently needed
  85. Can antiretroviral therapy be safely interrupted and, if so, when?
  86. Silica Exposure and Silicosis: Action is Needed Now
  87. Antiretroviral therapy in low-resource settings
  88. Time for universal HIV and HBV screening for patients with cancer
  89. Editorial: [Challenges in Infectious Diseases in Low and Middle-Income Countries]
  90. The challenge of lymphomas in sub-Saharan Africa
  91. PriorMycobacterium aviumcomplex infection is linked to immunological nonresponsiveness in HIV-infected patients on highly active antiretroviral therapy
  92. Lymph nodes and pathogenesis of infection with HIV-1
  93. The need for new antibiotics
  94. No Influence of Nevirapine on Vitamin D Deficiency in HIV-Infected Patients
  95. The bacterium that could cause cancer
  96. Diagnosis, management and outcome of clinically- suspected spinal infection
  97. Maraviroc and CD4+ cell count recovery in patients with virologic suppression and blunted CD4+ cell response
  98. Human herpesvirus type 6 hepatitis or familiar intrahepatic cholestasis: the importance of follow-up
  99. Viral Encephalitis: Etiology, Clinical Features, Diagnosis and Management
  100. Micafungin - The newest echinocandin
  101. Letter to the Editor: Darunavir-Etravirine-Raltegravir as Salvage Combination Therapy in a Heavily Pretreated HIV-Infected Patient
  102. Perspectives in therapy for hepatitis C
  103. Lung infections after cancer chemotherapy
  104. Aminotransferases as predictors of mortality
  105. Does tenofovir increase efavirenz hepatotoxicity?
  106. Initial Hospitalization and Adherence to Highly Active Antiretroviral Therapy
  107. Voluntary or Universal HIV Testing in Italy?
  108. Etravirine
  109. Life-threatening, Multiple Hypersensitivity Reactions Induced by Rifampicin in One Patient with Pulmonary Tuberculosis
  110. Discontinuation of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy: clinical implications in patients on CD4 T-cell-guided treatment interruption
  111. Selective Drug Taking During Combination Antiretroviral Therapy
  112. Intracranial mass lesions in HIV/AIDS patients from developing countries endemic for neurocysticercosis
  113. Approach to salvage antiretroviral therapy in heavily antiretroviral-experienced HIV-positive adults
  114. Co-occurrence of chronic hepatitis B virus infection and autoimmune hepatitis in a young Senegalese girl
  115. Tenofovir-Associated Kidney Diseases and Interactions between Tenofovir and Other Antiretrovirals
  116. Infections and thalassaemia
  117. Hyperacute Unilateral Gonococcal Endophthalmitis in an HIV-Infected Man without Genital Infection
  118. Clinical course of infection with hepatitis C
  119. Human Immunodeficiency Virus-Associated Peripheral Neuropathies
  120. Interleukin-2 therapy and CD4+ T cells in HIV-1 infection
  121. Acute liver failure as presenting feature of tyrosinemia type 1 in a child with primary HHV-6 infection
  122. CHILDHOOD HEPATITIS C VIRUS INFECTION.
  123. Recreational substance use and tolerance of efavirenz in HIV-1 infected patients
  124. Cutaneous abscess due to in injection drug user: a case report and review of the literature
  125. Strongyloidiasis in an HIV‐1–Infected Patient after Highly Active Antiretroviral Therapy–Induced Immune Restoration
  126. Tipranavir
  127. Antinuclear antibodies are common in an infectious environment but do not predict systemic lupus erythematosus
  128. Can We Really Identify HIV-1 Long-Term Nonprogressors?
  129. Painful Neuropathy Vasculitis in 2 Patients with Long-Standing Human Immunodeficiency Virus-1 Infection
  130. Early detection of lung cancer in high-risk patients with HIV-1 infection
  131. Autoimmune hemolytic anemia and autoimmune hepatitis associated with parvovirus B19 infection
  132. Is there a role for viruses in triggering autoimmune hepatitis?
  133. Infections in patients with cancer undergoing chemotherapy: aetiology, prevention, and treatment
  134. Is there a role for TNF-alpha in HIV1-associated lipodystrophy?
  135. Unusual, rapidly growing ulcerative genital mass due to herpes simplex virus in a human immunodeficiency virus-infected woman
  136. Management of Health Care Workers With Blood-Borne Infections
  137. Hepatitis C virus in people with HIV infection
  138. Blood-Borne Viruses and Health Care Workers
  139. Sequelae and Serologic Outcome in Persons with Hepatitis B Virus Infection
  140. Erratum
  141. Infections and solid organ transplant rejection: a cause-and-effect relationship?
  142. Hepatitis C is not a sexually transmissible disease
  143. Long-term efficacy of dual nucleoside reverse transcriptase inhibitor antiretroviral therapy in HIV-1 infection
  144. Treatment of autoantibody-associated chronic hepatitis C
  145. Hepatitis C is not a sexually transmissible disease
  146. Treatment of autoantibody-associated chronic hepatitis C
  147. Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue
  148. Childhood Infections and Autoimmune Diseases
  149. Does hepatitis C virus cause severe liver disease only in people who drink alcohol?
  150. How tainted is medicine?
  151. Full Adherence to HAART: Is It Really Necessary?
  152. BCG efficacy and tuberculin skin testing
  153. A Case of Visceral Leishmaniasis with Protracted Incubation in a Nonendemic Area
  154. Mortality Due to Hepatitis C Virus–Related Cirrhosis in Patients Infected with HIV Type 1: A Role for Alcohol
  155. MHC Class I Molecules and Progression to AIDS
  156. Hepatitis A Virus Infection and Atherosclerosis
  157. Isolated Presence of Antibody to Hepatitis B Core Antigen in Injection Drug Users: Do They Need to Be Vaccinated?
  158. Tuberculous chorioretinitis
  159. Failure of lamivudine therapy for chemotherapy-induced reactivation of Hepatitis B
  160. No Increase in Liver Decompensation Risk with Atypical Hepatitis C Virus Antibody Pattern
  161. Failure of lamivudine therapy for chemotherapy-induced reactivation of Hepatitis B
  162. HIV-1 progression in hepatitis-C-infected drug users
  163. Effect of pregnancy on chronic hepatitis C
  164. Cryptococcal meningitis during cyclosporin treatment in a patient with psoriasis
  165. Nosocomial Candidemia in Non-Neutropenic Patients at an Italian Tertiary Care Hospital
  166. Coxsackie B virus-induced autoimmunity to GAD does not lead to type 1 diabetes
  167. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C
  168. Recovery of long-term natural protection against reactivation of CMV retinitis in AIDS patients responding to highly active antiretroviral therapy
  169. Mediastinal Lymphadenitis due To Cryptococcal Infection In HIV-Positive Patients On Highly Active Antiretroviral Therapy
  170. Correspondence
  171. Adherence to HAART in HIV
  172. Failure of Prophylaxis against PCP in Patients with HIV Infection
  173. Hepatitis Associated with Hepatitis A Superinfection in Patients with Chronic Hepatitis C
  174. Response of uncomplicated falciparum malaria to oral chloroquine and quinine in Burundi highlands
  175. Highly active antiretroviral therapy
  176. Fluconazole penetration into the prostatic fluid of patients with AIDS- associated cryptococcal meningitis
  177. Syphilis in prostitutes from Eastern Europe
  178. Tuberculosis Among Refugees and Displaced People at the Burundi‐Rwanda Border
  179. Fulminant Hepatitis Associated with Hepatitis A Virus Superinfection in Patients with Chronic Hepatitis C
  180. Autoimmune hepatitis type 2 induced by HCV and persisting after viral clearance
  181. Microsporidium Species in Pulmonary Cavity Lesions of AIDS Patient Infected withRhodococcus equi
  182. Comparative evaluation of naturally occurring Pneumocystis carinii pneumonia (PCP) and PCP despite primary chemoprophylaxis in patients with AIDS
  183. The ParaSight™-F rapid dipstick antigen capture assay for monitoring parasite clearance after drug treatment of Plasmodium falciparum malaria
  184. Aetiology of pneumonia following isolated closed head injury
  185. Steroid and interferon therapy in liver/kidney microsomal antibody-positive patients with chronic hepatitis C
  186. Infection with hepatitis G virus in immunoglobulin recipients
  187. M tuberculosis drug resistance in AIDS
  188. Resolution of autoimmune hepatitis after bone-marrow transplantation
  189. Twice-weekly dapsone for primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1 infection: efficacy, safety and pharmacokinetic data
  190. Comparative histopathological study of pulmonary tuberculosis in human immunodeficiency virus-infected and non-infected patients
  191. Lack of Sustained Efficacy of Interferon in Patients with Chronic Hepatitis C
  192. Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus
  193. Discordant Manifestations of Hepatitis C in Monozygotic Twins
  194. Epstein-Barr virus as a trigger for autoimmune hepatitis in susceptible individuals
  195. Naturally acquired immunity to Plasmodium falciparum
  196. Multidrug-Resistant Tuberculosis in Patients With AIDS
  197. Multidrug-resistant tuberculosis in patients with AIDS
  198. Pentoxifylline as a Supportive Agent in the Treatment of Cerebral Malaria in Children
  199. West African Immigrants and New Patterns of Malaria Imported to North Eastern Italy
  200. Manifestations of TB to CD4 cell counts.
  201. Prognosis of vertically transmitted pre-core mutant HBV infection
  202. Pneumocystis carinii pneumonia during primary HIV-1 infection
  203. Rapid decline of CD4+ cells after IFNα treatment in HIV-1 infection
  204. Transmission of HIV-Associated Tuberculosis to Healthcare Workers
  205. Hepatitis C viraemia with normal liver histology in symptomless HIV-1 infection
  206. Use of fluconazole in the treatment ofCandida albicans hydrocephalus shunt infection
  207. Failure of the 12 months course of antituberculous chemoprophylaxis in HIV infection
  208. Tuberculosis and HIV Infection
  209. Identification of hepatitis A virus as a trigger for autoimmune chronic hepatitis type 1 in susceptible individuals
  210. Survival after Active Tuberculosis in Patients with HIV Infection
  211. Cellular mechanisms of hepatocyte damage and regulatory mechanisms in autoimmune chronic active hepatitis
  212. Type 2 autoimmune hepatitis and hepatitis C virus infection
  213. HAZARDS OF INTERFERON THERAPY FOR HBV-SERONEGATIVE CHRONIC HEPATITIS
  214. REACTIVATION OF HEPATITIS B IN AIDS
  215. CLINICAL REACTIVATION OF HEPATITIS B IN ANTI-HBs-POSITIVE PATIENTS WITH AIDS
  216. PATHOGENESIS OF TYPE I DIABETES
  217. Serial study of liver-directed autoantibodies and autoreactive T-lymphocytes in acute viral hepatitis B
  218. Sequential studies of pre-S2 antigenemia and anti-pre-S2 antibodies in relation to viral replication in acute hepatitis B followed from the early incubation phase
  219. In vitro effect of TP-1 (a calf thymic extract) on suppressor T-cell function of patients with autoimmune chronic active hepatitis
  220. Relevance of immune mediated mechanisms in progressive alcoholic liver injury
  221. PROSPECTIVE STUDY OF CELLULAR IMMUNITY TO HEPATITIS-B-VIRUS ANTIGENS FROM THE EARLY INCUBATION PHASE OF ACUTE HEPATITIS B
  222. T-CELL INDUCERS OF SUPPRESSOR LYMPHOCYTES CONTROL LIVER-DIRECTED AUTOREACTIVITY
  223. CELL-MEDIATED IMMUNITY AND SUPPRESSOR-T-CELL DEFECTS TO LIVER-DERIVED ANTIGENS IN FAMILIES OF PATIENTS WITH AUTOIMMUNE CHRONIC ACTIVE HEPATITIS
  224. T lymphocyte sensitization to hbcag and T cell-mediated unresponsiveness to HBsAg in hepatitis B virus-related chronic liver disease
  225. ANTIGEN SPECIFIC SUPPRESSOR CELL FUNCTION IN AUTOIMMUNE CHRONIC ACTIVE HEPATITIS